Central Neurocytoma Treatment Modalities: A Systematic Review Assessing the Outcomes of Combined Maximal Safe Resection and Radiotherapy with Gross Total Resection

Abstract

Central neurocytomas (CNCs) are rare intraventricular lesions comprising <1% of primary brain tumors. Their surgical and adjuvant management is unclear. Our goal was to update Rades etal.'s 2006 systematic review to assess the outcome differences among 3 fundamental therapies for CNC: gross total resection with and without radiation therapy (RT) versus maximal safe resection with adjuvant RT. Articles indexed on PubMed and Google Scholar and published between January 1, 2006 and December 31, 2019 were selected using the PRISMA criteria. Studies were excluded if they had fewer than 3 cases, did not categorize extent of resection, or were duplicate studies, technical reports, case reports, or studies without follow-up. Complication rates, recurrence rates, overall survival and progression-free survival were extracted where possible. χ2 proportionality tests were used for comparison (P values >0.05 suggested significance). On aggregation, 615 patients from 13 studies including ours were assessed. Although overall survival was not significantly different (χ2= 1.56; P= 0.46), the recurrence rate differed significantly between GTR+ RT (6.9%, 92.11 months), GTR-RT (23.9%, 96.8 months), and MSR+ RT (16.8%, 85 months) (χ2= 10.94; P= 0.004). Pooled complication rates for GTR and MSR+ RT were 31.2% and 24% (P=0.049), respectively. RT remains an important adjuvant treatment that can improve patient survival in the presence of MSR to levels comparable to those of GTR or GTR+ RT. Where total resection carries too much risk, MSR+ RT can be considered as the next best alternative for tumor control.